Tremors as a side effect of nebulized bronchodilators
Pro Research Analysisby 
Searched over 200M research papers
Tremors as a Common Side Effect of Nebulized Bronchodilators
Tremor, or shakiness, is a well-recognized and frequent side effect of nebulized beta-2 agonist bronchodilators such as salbutamol, terbutaline, fenoterol, and bitolterol. This effect is primarily due to stimulation of beta-adrenoceptors in skeletal muscle and is generally reversible and dose-dependent 1234567.
Incidence and Intensity of Tremor with Different Bronchodilators
Studies comparing salbutamol, terbutaline, and fenoterol in children and adults have consistently found that all three drugs can cause rapid onset of tremor, often within 5 minutes of administration by nebulizer 14. The intensity of tremor may be greater with higher doses or with certain drugs, such as salbutamol, especially when administered at doses higher than typically recommended . Fenoterol and salbutamol have shown similar side effect profiles, with tremor being the most common, although at the highest doses, fenoterol may cause slightly more tremor . Bitolterol also causes tremor, and the risk increases with higher doses, with no additional bronchodilator benefit beyond a certain dose .
Dose-Dependence and Route of Administration
The likelihood and severity of tremor are closely related to the dose of the bronchodilator administered. Higher doses, especially when delivered by nebulization, are associated with more intense tremor 247. The inhaled route is generally preferred because it delivers the drug directly to the airways, minimizing systemic side effects, but even with inhaled or nebulized therapy, tremor remains the most frequent dose-limiting side effect 56.
Comparison with Other Side Effects
While tremor is the most common side effect, other systemic effects such as increased heart rate (tachycardia) and palpitations can also occur, particularly at higher doses 1456. However, tremor is usually the first and most noticeable side effect, and it can be reduced by starting with a lower dose or switching to a different beta-2 agonist if it persists 56.
Newer Bronchodilators and Reduced Tremor
Emerging treatments, such as the inhaled PDE3/4 inhibitor RPL554, have shown similar bronchodilator effects to high-dose nebulized salbutamol but with a much lower incidence of tremor and other systemic side effects . This suggests that newer agents may offer effective bronchodilation with improved tolerability.
Clinical Implications and Management
Tremor associated with nebulized bronchodilators is generally mild and reversible, but it can be bothersome and may limit the dose that can be comfortably used. Careful dose titration and consideration of alternative agents can help minimize this side effect. In most cases, the benefits of effective bronchodilation outweigh the discomfort of mild tremor, but patient tolerance should guide therapy 56.
Conclusion
Tremor is a common, dose-related, and reversible side effect of nebulized beta-2 agonist bronchodilators. It occurs rapidly after administration and is most pronounced at higher doses or with certain drugs. While usually mild, tremor can be minimized by using the lowest effective dose and considering alternative agents if necessary. Newer bronchodilators may offer similar efficacy with fewer systemic side effects, including tremor.
Sources and full results
Most relevant research papers on this topic